Glaxosmithkline Intellectual Property Development Limited

Glaxosmithkline LLC

Yale University

Cambridge Enterprise Limited University of Cambridge

Glaxo Group Limited

Sebastien Andre Campos

John David Harling

Julie Nicole Hamblin

Andrew Sharpe

Vipulkumar Kantibhai Patel

Anthony William James Cooper

Niall Andrew Anderson

Simon Peace

Edward Paul Cannons

Diane Mary Coe

Craig M Crews

Ann Louise Walker

John Liddle

Dennis Buckley

Paul Bamborough

Ian Edward David Smith

Nicholas Paul Barton

Armelle Le Gall

Joelle Le

William L Jorgensen

Michael David Barker

Stephen Swanson

Jeremy John Payne

John Martin Pritchard

Graham George Adam Inglis

Kenneth David Down

Gemma Victoria White

Afjal Hussain Miah

Naimisha Trivedi

Denton Wade Hoyer

Caroline Whitworth

Heather Hobbs

Paul Faulder

Duncan Stuart Holmes

Julien Michel

Peter C Gareiss

Jeffrey Gustafson

Hyun-Seop Tae

Inge Van Molle

Alessio Ciulli

Anke G Roth

Michael John Johnston

William Jorgensen

Craig Crews

Dentin Wade Hoyer

Ian Edward Smith

The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular PI3-kinase activity.

Chemical compounds

The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins that are degraded and/or otherwise inhibited by bifunctional compounds of the present invention. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand that binds to the ubiquitin ligase and on the other end a moiety that binds a target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. The present invention exhibits a broad range of pharmacological activities associated with compounds of the present invention, consistent with the degradation/inhibition of targeted polypeptides.

Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an E3 ubiquitin ligase

A compound of formula (I): or a pharmaceutically acceptable salt thereof, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, for example as inhibitors of the activity of the estrogen receptor, including degrading the estrogen receptor, the treatment of diseases and conditions mediated by the estrogen receptor.

Compounds

Benzothiophene derivatives as estrogen receptor inhibitors

The present invention relates to compounds of formula (I): wherein Ris Calkylamino, or Calkoxy; m is an integer having a value of 3, 4, or 5; n is an integer having a value of 0 to 3; p is an integer having a value of 1 or 2 and salts thereof are inducers of human interferon. Compounds which induce human interferon may be useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions for example allergic rhinitis and asthma, the treatment of infectious diseases and cancer, and may also be useful as vaccine adjuvants.

Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases

Compounds of formula (I): are inhibitors of p38 kinase and are useful in the treatment of conditions or disease states mediated by p38 kinase activity or mediated by cytokines produced by the activity of p38.

Fused heteroaryl derivatives for use as p38 kinase inhibitors in the treatment of I.A. rheumatoid arthritis

Growing community of inventors

Stevenage, United Kingdom

Sebastien Andre Campos